Published on: November 19, 2026
Categorized as: Research
Why Every Suspected EHE Case Needs an Expert Pathologist Review
A recent editorial shared a case series of liver EHE from Aga Khan University Hospital in Karachi as a stark reminder of something we say often at the EHE Foundation: epithelioid hemangioendothelioma is challenging to diagnose, and getting the diagnosis wrong has real consequences.
In the case series, from 14 years of records, the hospital's pathology team identified seven cases of hepatic EHE. In each case, the initial working diagnosis before biopsy was wrong, and clinicians suspected a more common metastatic carcinoma or multifocal hepatocellular carcinoma instead. EHE affects fewer than one person in a million, so many oncologists and pathologists will encounter it rarely, if ever, in their careers.
That is exactly why tissue analysis matters. Several methods can reliably confirm an EHE diagnosis, including genomic sequencing, targeted fusion testing, immunohistochemical staining, or a combination of the three. At minimum, confirming EHE requires a biopsy with immunohistochemical staining for endothelial markers like ERG, CD31, and CD34, as well as CAMTA1. This is the only way to reliably distinguish it from carcinoma under a microscope. And the stakes of that distinction are high: hepatocellular carcinoma and other carcinomas follow well-established treatment protocols, while EHE behaves very differently and calls for a different approach entirely.
For clinicians making a diagnosis and for people diagnosed with EHE, this is an important reminder: consult experts who specialize in diagnosing and treating sarcomas before making any other care decisions. Visit our new EHE 101 website page to learn more about diagnosing EHE and the importance of finding an experienced pathologist to review and confirm your diagnosis.


